A kidney drug could help far more patients than previously thought

Expanding the use of a previously limited kidney treatment

For a long time, the clinical response to kidney disease depended on one major factor: the presence of type 2 diabetes. According to a report by Earth.com, a specific prescription could slow kidney damage in these patients, while treatment options were almost entirely unavailable for people with kidney conditions of other origins.

The treatment in question, finerenone, works by inhibiting a hormonal signal directly linked to inflammation and scar tissue formation in the kidneys. By reducing this physiological activity, the drug helps preserve kidney function over the long term. Regulatory authorities had initially approved its use for a single purpose: to protect the kidneys of individuals whose kidney disease resulted from type 2 diabetes.

Previous clinical trials had indeed demonstrated its effectiveness in reducing the risk of cardiac and renal complications in this specific group. Since diabetes is only one of many causes of kidney damage, a large proportion of patients losing kidney function for other reasons faced a severe lack of validated medical options.

The FIND-CKD Study and Its Large-Scale Methodology

To explore new therapeutic avenues, Professor Hiddo J.L. Heerspink, a researcher at the George Institute for Global Health, sought to determine whether finerenone could benefit patients with other medical profiles. The research project that emerged from this question, called FIND-CKD, recruited 1,584 adults whose kidney disease was unrelated to diabetes.

These volunteers, from 24 different countries, continued taking their usual medications throughout the study. In addition to their standard care, half of the group received finerenone, while the other half was given a placebo—that is, an inactive pill containing no active ingredient.

The study was conducted over a period of nearly three years using a double-blind method: neither the patients nor their treating physicians knew which pill was being administered. This design made FIND-CKD the first large-scale clinical trial to evaluate the impact of finerenone on a non-diabetic population, providing unprecedented data for patients awaiting treatment options.

Significant clinical results and converging analyses

Data collected over the course of several months revealed that the kidneys of patients treated with finerenone were more resilient to the disease. Although their filtration capacity continued to decline—a process inherent to kidney disease—this decline occurred much more slowly than in the placebo group. The most compelling result comes from the combined count of the most severe complications, including kidney failure, sudden worsening of the disease, heart failure, and deaths related to heart problems.

As Earth.com points out, individuals on finerenone had a roughly 23% lower probability of experiencing one of these critical events compared to those on placebo. These results were published on the same day as two complementary analyses in three of the most respected medical journals, constituting a particularly rare event in the field of research.

One of these analyses, led by Professor Brendon L. Neuen, combined data from the FIND-CKD trial with those from two previous studies on diabetes, totaling 14,574 patients. The benefits were consistent regardless of whether the participants had diabetes or not. Another analysis focusing on glomerular diseases—where the immune system attacks the kidneys’ filtration units—showed that the drug reduced the risk of kidney failure or worsening by about a quarter and decreased protein leakage into the urine by about 40% over the course of a year.

Potassium Level Management and Treatment Tolerance

Any pharmacological intervention involves physiological trade-offs, and the main side effect associated with finerenone manifests in blood composition. The treatment can indeed cause elevated potassium levels, a clinical condition that doctors call hyperkalemia.

Since high potassium levels can disrupt the heart’s natural rhythm, this side effect requires close medical monitoring. A review of various studies confirmed that this phenomenon occurred more frequently in patients taking the active ingredient than in those receiving a placebo.

Despite this increased frequency, potassium levels rarely reached a severe stage. Very few patients were forced to discontinue their treatment, and hospitalizations directly related to hyperkalemia remained uncommon. These findings allowed the research teams to conclude that the drug was generally well-tolerated by participants.

Global Impact and Prospects for Changes in Medical Guidelines

The attention given to these new data stems from the alarming statistics surrounding kidney disease. According to a scientific journal, this condition affects more than one in ten people worldwide—approximately 850 million individuals—and its prevalence as a cause of death continues to rise. Projections estimate that it will rank among the top five causes of premature death by the year 2040.

The majority of these patients—representing between half and two-thirds of cases—have never been diagnosed with diabetes and have consequently been excluded from many treatment protocols in the past. Results published in The New England Journal of Medicine now show that a drug already available in pharmacies can slow the disease and reduce the risk of serious complications in this large population.

Professor Neuen argued that wider use of finerenone could prevent kidney failure and cardiac complications for millions of people worldwide. If medical guidelines are updated to reflect this new clinical evidence, the patients who will benefit the most will be those who, until now, have had very few alternatives. For any medical questions, consult a qualified healthcare professional.

Source: earth.com

A kidney drug could help far more patients than previously thought